Literature DB >> 10639272

Low-Dose Vitamin K Therapy in Excessively Anticoagulated Patients: A Dose-Finding Study.

.   

Abstract

Rapid reduction of excessively high international normalized ratio (INR) values into the therapeutic range is necessary in patients who must be maintained on oral anticoagulants but who present with an overdose. We prospectively studied the effect of observation alone versus escalating low doses of intravenous vitamin K on 23 patients presenting with no overt evidence of hemorrhage and INR values in excess of 10. Two of six patients observed without intervention developed spontaneous hemorrhage. Only one of the observed patients and none of 4 patients given 100-200 µg-vitamin K had INR values less than 5.0 by 24 hours. Three of the four patients receiving 500 µg of vitamin K had INR values less than 5.0, with two of these being less than 3.5 within the first 24 hours. Nine patients receiving 1000 µg of vitamin K had INR values between 1.7 and 3.5 by 24 hours. In none of these nine patients did the INR subsequently normalize, and there were no difficulties re-establishing anticoagulant therapy. No adverse effects were noted in any of the patients receiving intravenous vitamin K. We recommend 1000 µg of intravenous vitamin K as a safe and effective means of rapidly reversing excessively anticoagulated patients presenting with INR values greater than 10 units.

Entities:  

Year:  1997        PMID: 10639272     DOI: 10.1023/a:1008811421946

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

Review 1.  Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

2.  Acute cardiovascular collapse after intravenous phytonadione.

Authors:  P Barash; L M Kitahata; S Mandel
Journal:  Anesth Analg       Date:  1976 Mar-Apr       Impact factor: 5.108

3.  [Shock states during injection of vitamin K].

Authors:  A Labatut; F Sorbette; C Virenque
Journal:  Therapie       Date:  1988 Jan-Feb       Impact factor: 2.070

4.  Anaphylactic shock and vitamin K1.

Authors:  J de la Rubia; E Grau; I Montserrat; I Zuazu; A Payá
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

5.  Severe complications of intravenous phytonadione therapy. Two cases, with one fatality.

Authors:  E C Rich; C W Drage
Journal:  Postgrad Med       Date:  1982-11       Impact factor: 3.840

6.  Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation.

Authors:  V Pengo; A Banzato; E Garelli; A Zasso; A Biasiolo
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

Review 7.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

8.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

Authors:  J N Saour; J O Sieck; L A Mamo; A S Gallus
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245

9.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

10.  Comparison of two levels of anticoagulant therapy in patients with substitute heart valves.

Authors:  R Altman; J Rouvier; E Gurfinkel; O D'Ortencio; R Manzanel; L de La Fuente; R G Favaloro
Journal:  J Thorac Cardiovasc Surg       Date:  1991-03       Impact factor: 5.209

View more
  5 in total

1.  Management of hemorrhagic events in patients receiving anticoagulant therapy.

Authors:  D G Love
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Pharmacotherapy Pearls for Emergency Neurological Life Support.

Authors:  Gretchen M Brophy; Theresa Human
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 3.  Warfarin reversal.

Authors:  J P Hanley
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 4.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 5.  Emergency Neurological Life Support: Pharmacotherapy.

Authors:  Gretchen M Brophy; Theresa Human; Lori Shutter
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.532

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.